EPHB2 and breast carcinoma: High cytoplasmic EPHB2 expression predicted shorter distant metastasis-free survival, H.R. (95%CI)=1.37 (0.92-2.04), P=0.12 and poor breast cancer survival, H.R. (95%CI)=1.52 (0.10-2.33), P=0.05 (Fig. 4E, 4F).